Lilly’s $2.3B JAK2 Bet Just Showed Its First Cards — and the Myelofibrosis Market Won’t Be the Same
Lilly's AJ1-11095 hit 70% spleen volume reduction in post-ruxolitinib patients at EHA 2026, threatening Incyte's $1.5B ruxolitinib franchise with...